Jillian Patton
Family Medicine · Floresville, TXNPI 1801324124
Payments from drug & device makers
Across 133 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$648
- Lilly USA, LLC$643
- Novo Nordisk$178
- GSK$112
- Pfizer$90
- Merck$80
- plus $497 from 15 others
What the payments were for
- Food & beverage$2,249100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 43 | $648 |
| Lilly USA, LLC | 33 | $643 |
| Novo Nordisk | 9 | $178 |
| GSK | 8 | $112 |
| Pfizer | 5 | $90 |
| Merck | 5 | $80 |
| AstraZeneca | 5 | $80 |
| Sanofi Pasteur Inc. | 3 | $78 |
| Currax Pharmaceuticals LLC | 5 | $64 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $38 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Amgen | 2 | $34 |
| Convatec Inc. | 2 | $29 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Sanofi | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Cranial Technologies, Inc | 1 | $16 |
| Corium, LLC | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Organon | 1 | $8 |
How this compares
$2,249 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 198 | $203,510 |
| MounjaroTirzepatide | 102 | $113,423 |
| TrulicityDulaglutide | 80 | $94,794 |
| JardianceEmpagliflozin | 55 | $79,112 |
| EliquisApixaban | 30 | $37,628 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $35,265 |
| JanuviaSitagliptin Phosphate | 23 | $25,739 |
| MyrbetriqMirabegron | 35 | $21,170 |
| RexultiBrexpiprazole | 12 | $20,485 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $13,443 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $9,124 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $3,575 |
| Duloxetine Hcl | 95 | $3,548 |
| Gabapentin | 151 | $3,303 |
| Rosuvastatin Calcium | 206 | $3,234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $643 | $208,217182 claims |
| Novo NordiskOzempic | $178 | $203,510198 claims |
| PfizerEliquis | $90 | $37,62830 claims |
| GSKTrelegy Ellipta | $112 | $35,26548 claims |
| MerckJanuvia | $80 | $25,73923 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $21,17035 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Floresville
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.